Assessing the Value of Pharmaceuticals
There is increased interest in the question of whether pharmacoeconomic studies that measure the value of drug therapies affect clinical decisions and payer policies.
How Government Pricing Professionals Became Pharmaceutical Industry Change Agents
The world of government pricing (GP), once a mystery to many in the pharmacy industry, is considered to be a key component of strategic and compliance activity. For pharmaceutical manufacturers, government business is a top priority.
Maintaining Compliance in the Global Pharmacovigilance Landscape
A satisfactory system for the collection and reporting of adverse events is increasingly important as manufacturers place additional requirements on their specialty pharmacy and health care provider partners, and these needs go beyond the United States.
Financial Accruals in the Specialty Pharmaceutical Industry: The Case for Automating the Process
As payers and providers are required to provide real-world outcomes data, there is high demand for the detailed financial reporting that an automated financial accruals process can produce. Here's what stakeholders need to know about the process.
Specialty Pharmacy Core URAC Standards Overview, Part 3
This overview focuses on human resources issues, including those related to staff licensures and job descriptions, as they apply to URAC specialty pharmacy core standards accreditation.
Specialty Trends to Consider
Distribution models are the key drivers for new participants in the specialty space. Here’s a thoughtful discussion on how to grow your business.
Dysfunction in Washington, DC
The Affordable Care Act continues to be the subject of bitter dispute.
Specialty Pharmacy Considerations for Oral Multiple Sclerosis Therapies
Multiple sclerosis treatment options have expanded dramatically over the past several years. In addition to subcutaneous and intravenous medications, there are now 3 disease-modifying oral therapies available in the United States.
Improving Transplant Care Outcomes
For transplant patients, the difference between a successful and an unsuccessful outcome can be made by medication adherence.
Near-Term Specialty Pipeline Highlights
A significant number of new specialty medications are on track to be approved in 2013, and some will provide increased competition in certain therapy classes.
Boehringer Ingelheim Pharmaceuticals’ Gilotrif
Gilotrif (afatinib) is a first-line oral treatment for certain non-small cell lung cancers.